Barlow Wealth Partners LLC Raises Holdings in McKesson Corporation $MCK

Barlow Wealth Partners LLC increased its stake in shares of McKesson Corporation (NYSE:MCK) by 7.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,123 shares of the company’s stock after acquiring an additional 1,236 shares during the quarter. McKesson makes up 1.5% of Barlow Wealth Partners LLC’s investment portfolio, making the stock its 28th largest position. Barlow Wealth Partners LLC’s holdings in McKesson were worth $13,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of MCK. Obsidian Personal Planning Solutions LLC increased its stake in shares of McKesson by 2.9% during the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after buying an additional 12 shares during the period. IAM Advisory LLC lifted its stake in McKesson by 0.3% in the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after acquiring an additional 13 shares during the period. PDS Planning Inc lifted its stake in McKesson by 1.1% in the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after acquiring an additional 13 shares during the period. Berkshire Asset Management LLC PA boosted its holdings in McKesson by 4.6% in the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after acquiring an additional 13 shares in the last quarter. Finally, Norden Group LLC increased its position in McKesson by 4.3% during the 4th quarter. Norden Group LLC now owns 317 shares of the company’s stock valued at $260,000 after purchasing an additional 13 shares during the period. 85.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,868 shares of company stock worth $3,743,820. Insiders own 0.08% of the company’s stock.

Wall Street Analysts Forecast Growth

MCK has been the subject of a number of research reports. Barclays increased their price target on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Weiss Ratings downgraded McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. JPMorgan Chase & Co. increased their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Finally, Morgan Stanley restated an “overweight” rating and set a $966.00 price target on shares of McKesson in a research report on Thursday, January 29th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and an average target price of $960.93.

McKesson Trading Up 0.0%

Shares of MCK stock opened at $860.41 on Monday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The stock has a market capitalization of $105.39 billion, a P/E ratio of 24.75, a P/E/G ratio of 1.38 and a beta of 0.38. The firm’s 50 day moving average is $907.62 and its 200 day moving average is $840.69.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the prior year, the business earned $8.03 earnings per share. McKesson’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts predict that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.